EA015933B1 - Лечение детских опухолей - Google Patents

Лечение детских опухолей Download PDF

Info

Publication number
EA015933B1
EA015933B1 EA201070193A EA201070193A EA015933B1 EA 015933 B1 EA015933 B1 EA 015933B1 EA 201070193 A EA201070193 A EA 201070193A EA 201070193 A EA201070193 A EA 201070193A EA 015933 B1 EA015933 B1 EA 015933B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumor
tumors
treatment
children
drug
Prior art date
Application number
EA201070193A
Other languages
English (en)
Russian (ru)
Other versions
EA201070193A1 (ru
Inventor
Клаудио Пизано
Лоредана Веши
Паоло Карминати
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA201070193A1 publication Critical patent/EA201070193A1/ru
Publication of EA015933B1 publication Critical patent/EA015933B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201070193A 2007-08-01 2008-07-03 Лечение детских опухолей EA015933B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113603 2007-08-01
PCT/EP2008/058601 WO2009015981A2 (en) 2007-08-01 2008-07-03 Treatment of pediatric tumors

Publications (2)

Publication Number Publication Date
EA201070193A1 EA201070193A1 (ru) 2010-06-30
EA015933B1 true EA015933B1 (ru) 2011-12-30

Family

ID=38799381

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070193A EA015933B1 (ru) 2007-08-01 2008-07-03 Лечение детских опухолей

Country Status (11)

Country Link
US (1) US8829021B2 (cg-RX-API-DMAC7.html)
EP (1) EP2182951A2 (cg-RX-API-DMAC7.html)
JP (2) JP5765937B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100051837A (cg-RX-API-DMAC7.html)
CN (1) CN101784277A (cg-RX-API-DMAC7.html)
BR (1) BRPI0815051A2 (cg-RX-API-DMAC7.html)
CA (1) CA2694389C (cg-RX-API-DMAC7.html)
EA (1) EA015933B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001084A (cg-RX-API-DMAC7.html)
SG (1) SG183010A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009015981A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
JP2017519770A (ja) 2014-06-18 2017-07-20 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティ オブ アリゾナ Ｏｄｃ１遺伝子型に基づく癌腫の診断および処置
US20190046484A1 (en) * 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
HK1258284A1 (zh) 2015-10-30 2019-11-08 癌症预防制药股份有限公司 依氟鸟氨酸和舒林酸，固定剂量的组合制剂
CN114096240A (zh) 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977A1 (en) * 1999-03-09 2000-10-18 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
WO2007071603A1 (en) * 2005-12-21 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977A1 (en) * 1999-03-09 2000-10-18 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
WO2007071603A1 (en) * 2005-12-21 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHITARA TOSHIJI ET AL.: "Irinotecan for children with relapsed solid tumors." PEDIATRIC HEMATOLOGY AND ONCOLOGY MAR 2006, vol. 23, no. 2, March 2006 (2006-03), pages 103-110, XP008086961 ISSN: 1521-0669 page 10.4, paragraph 2-4 page 106, paragraph 2; table 2 page 107, last paragraph - page 109, paragraph 3 *

Also Published As

Publication number Publication date
SG183010A1 (en) 2012-08-30
EA201070193A1 (ru) 2010-06-30
JP2010534699A (ja) 2010-11-11
CA2694389C (en) 2016-01-19
CN101784277A (zh) 2010-07-21
WO2009015981A3 (en) 2009-09-03
WO2009015981A2 (en) 2009-02-05
BRPI0815051A2 (pt) 2015-02-10
JP5765937B2 (ja) 2015-08-19
MX2010001084A (es) 2010-03-25
US20100197718A1 (en) 2010-08-05
CA2694389A1 (en) 2009-02-05
JP2014111653A (ja) 2014-06-19
US8829021B2 (en) 2014-09-09
AU2008282024A1 (en) 2009-02-05
EP2182951A2 (en) 2010-05-12
KR20100051837A (ko) 2010-05-18

Similar Documents

Publication Publication Date Title
JP2023503897A (ja) Ｎｒａｓ変異を有する腫瘍を治療するための医薬品の調製におけるｆａｋ阻害剤の使用
AU2002311985B2 (en) Methods for inhibiting angiogenesis
US6433012B1 (en) Method for inhibiting inflammatory disease
WO2004080462A1 (ja) c-Kitキナーゼ阻害剤
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
CA2782555C (en) 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
JP6911048B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
CN110652514A (zh) 第三代egfr抑制剂的制药用途
EA015933B1 (ru) Лечение детских опухолей
KR20210038906A (ko) 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
US20220047573A1 (en) Methods for treating vascular malformations
ES2745294T3 (es) Un polipéptido de Mormodica Charantia para su uso en la regulación de genes relacionados con la inflamación y el metabolismo de lípidos y de glucosa
JP2022529949A (ja) ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
WO2023104151A1 (zh) 治疗肿瘤的药物组合及用途
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
TWI891650B (zh) 治療血管畸形之方法
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
KR20250091332A (ko) 유비퀴틴-특이적 처리 프로테아제 1 (usp1) 억제제 및 parp1-선택적 억제제를 포함하는 치료적 조합물
CN114788829A (zh) 一种吡啶并[1,2-a]嘧啶酮类似物的应用
TWI671284B (zh) 治療大腸直腸癌的化合物
AU2008282024B2 (en) Treatment of pediatric tumors
CN118161509B (zh) 一种mapk12抑制剂及其衍生物在制备抗肿瘤药物中的应用
CN103142584B (zh) 多取代5-羟基吡咯酮类化合物在制备抗肿瘤的药物中的应用
CN107001258B (zh) 作为用于治疗癌症的治疗剂的4-氧代-n-(4-羟基苯基)视黄酰胺衍生物
CN116889568A (zh) 一种抗肿瘤联合用药物及其用途

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU